Tesaro rockets up after PARP inhibitor aces PhIII study and R&D rivalry intensifies
Tesaro’s closely-watched PARP inhibitor niraparib has aced its first Phase III challenge, racking up a slate of promising outcomes for progression-free survival for advanced, recurring ovarian cancer that will take it straight to the FDA — which has already approved a rival with much worse data.
“This is the first randomized Phase III of a PARP inhibitor to be successful,” says Mary Lynne Hedley, the president and COO of Waltham, MA-based Tesaro ($TSRO).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.